Chiong M A, Carpenter K, Christodoulou J
Western Sydney Genetics Program, Children's Hospital at Westmead, Locked Bag 4001, Westmead, NSW, 2145, Australia.
J Inherit Metab Dis. 2007 Jun;30(3):405. doi: 10.1007/s10545-007-0495-0. Epub 2007 Apr 3.
A newborn boy with family history of severe ornithine transcarbamylase (OTC) deficiency was investigated prospectively and managed aggressively at birth based on an existing protocol for at risk neonates. Undetectable citrulline levels at birth suggested that the infant was affected; however, normal plasma glutamine and urine orotic acid levels confused the diagnosis to some extent. Mutation testing confirmed that the patient did not have OTC deficiency. Thus the low plasma citrulline level did not validate our initial biochemical suspicion of OTC deficiency, and this highlights the importance of considering all available clinical, biochemical and molecular evidence in determining disease status.
一名有严重鸟氨酸转氨甲酰酶(OTC)缺乏家族史的男婴在出生时根据现有的高危新生儿诊疗方案进行了前瞻性研究并积极治疗。出生时无法检测到瓜氨酸水平提示该婴儿患病;然而,正常的血浆谷氨酰胺水平和尿乳清酸水平在一定程度上使诊断变得复杂。突变检测证实该患者没有OTC缺乏症。因此,低血浆瓜氨酸水平并不能证实我们最初对OTC缺乏症的生化怀疑,这突出了在确定疾病状态时考虑所有可用的临床、生化和分子证据的重要性。